🧬 Aging Wiki

epitalon

Properties1
aliasesEpithalon, Epithalone, Ala-Glu-Asp-Gly, AEDG, AEDG peptide

17 min read

Epitalon (Epithalon)

A synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG) based on the amino acid composition of epithalamin, a bovine pineal gland polypeptide extract. Studied primarily by Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology for ~25 years for geroprotective effects. Among the R36 12-peptide cluster, epitalon carries the strongest longevity-research attention due to telomerase-induction claims and a prospective mortality cohort — but both the cohort and most mechanistic data are Khavinson-group-sourced, and the cohort used the bovine extract, not the synthetic peptide.

Identity and nomenclature — critical disambiguation

Epitalon/Epithalon (this page) is a synthetic tetrapeptide with the defined sequence Ala-Glu-Asp-Gly (AEDG). It is a small, well-characterized molecule (MW 390.35 Da).

Epithalamin is the bovine pineal gland extract from which the AEDG sequence was derived. Epithalamin is a complex mixture of peptides; it is not the same compound as synthetic epitalon.

FeatureEpitalon (Epithalon)Epithalamin
TypeSynthetic tetrapeptideBovine pineal extract
SequenceAla-Glu-Asp-Gly (defined)Complex peptide mixture
PubChem CID219042N/A (not a single compound)
Use in the key mortality cohort?NoYes
Use in telomerase in-vitro studies?Yes (Khavinson 2003/2004)No

The 266-person mortality cohort cited in longevity-community literature used epithalamin, not synthetic epitalon. The frequent conflation of these in supplement marketing and secondary sources is a major source of misinformation. This wiki uses “epitalon” only for the synthetic AEDG tetrapeptide.

  • PubChem CID: 219042
  • Molecular formula: C14H22N4O9
  • Molecular weight: 390.35 Da
  • InChIKey: HGHOBRRUMWJWCU-FXQIFTODSA-N
  • Sequence: H-Ala-Glu-Asp-Gly-OH (N→C)
  • ChEMBL: No entry found (2026-05-09) needs-canonical-id
  • DrugBank: No entry found (2026-05-09) needs-canonical-id
  • WHO-INN: None assigned

Mechanism claims

Three primary mechanism claims appear in the literature. They are evaluated separately below.

1. Telomerase induction and telomere elongation

Claim: Synthetic epitalon induces expression of the telomerase catalytic subunit (TERT), restores telomerase enzymatic activity in telomerase-negative somatic cells, and results in telomere elongation.

Primary sources:

  • Khavinson et al. 2003 (PMID 12937682) added synthetic Epithalon (Ala-Glu-Asp-Gly) to telomerase-negative human fetal fibroblast culture and reported induction of TERT catalytic subunit expression, telomerase enzymatic activity, and telomere elongation 1. No quantitative elongation in base-pairs was reported in the abstract; no orthogonal assay (Southern blot, TeSLA) was described. The paper studied HeLa cells and fetal lung fibroblasts 602/17.
  • Khavinson et al. 2004 (PMID 15455129) extended this to primary pulmonary fibroblasts derived from a single 24-week fetus, which had lost proliferative potential at passage 34 2. Epithalon induced telomere elongation to a size comparable to early passages (passage 10) and treated cells made 10 extra divisions (reaching passage 44) compared to controls that arrested at passage 34. No bp-level quantification reported; single fetal donor source is a major limitation. The “10 extra divisions” claim is from passage 34 to passage 44 (not an absolute doubling number).
  • Al-Dulaimi et al. 2025 (PMID 40908429, Biogerontology) is the first independent replication attempt outside the Khavinson group 3. Using breast cancer cell lines (21NT, BT474) and normal epithelial (HMEC) and fibroblast (IBR.3) cells treated with 0.1–1.0 μg/mL epitalon, they found: (a) in normal cells, hTERT mRNA upregulation and significant telomerase activity increase (fourfold in IBR.3, 26-fold in HMEC) with telomere elongation; (b) in cancer cells, hTERT was elevated but telomerase enzyme activity was NOT significantly increased — instead, telomere length increased via ALT (Alternative Lengthening of Telomeres) activation (~10-fold in 21NT, ~3-fold in BT474 by C-circle assay). The study also notes an erratum (10.1007/s10522-025-10326-8). This is the strongest currently available independent evidence for the telomere-extension claim, but uses cell lines only.

Evidence quality assessment:

DimensionStatus
Pathway conserved in humans?Yes (TERT/telomerase mechanism is human)
Replicated independently?Partially — Al-Dulaimi 2025, cell-line level only
In vivo human evidence?No
Mechanism specificity?Unclear — how AEDG peptide engages TERT is not established

Khavinson 2005 (PMID 15990728) proposed a DNA-binding model: epitalon may directly bind the ATTTTC sequence in the TERT promoter region, acting as a transcriptional regulator 4. This is an intriguing but speculative in-silico/biophysical claim that has not been biochemically validated.

needs-replication — The core telomerase-induction claim rests on two small single-group Khavinson-lab fibroblast studies (single fetal donor; no control cell-line diversity; no quantitative bp elongation reported). Al-Dulaimi 2025 provides preliminary independent support but used cancer lines as the primary system.

no-mechanism — The molecular mechanism by which a 4-aa peptide activates TERT transcription in somatic cells is not established.

2. Antioxidant activity and ROS reduction

Claim: Epitalon acts as a potent antioxidant comparable to melatonin, reducing intracellular ROS.

  • Yue et al. 2022 (PMID 35413689, Aging (Albany NY)) tested 0.1 mM epitalon on post-ovulatory aging mouse oocytes 5. Findings: significantly reduced intracellular ROS (p<0.01 vs aged group); decreased spindle defects at 24h (significant; effect not significant at 12h); decreased abnormal cortical granule distribution at both 12h and 24h; increased mitochondrial membrane potential (p<0.01); increased mtDNA copy number (p<0.001); reduced early apoptosis. Higher concentrations (1–2 mM) unexpectedly failed to reduce ROS, suggesting a non-monotonic dose response. This is an independent study from Shanxi Medical University and Chinese Academy of Sciences State Key Lab of Stem Cell and Reproductive Biology; it does not address systemic aging but confirms antioxidant and mitochondria-protective activity in a mammalian cell system.
  • Gatta et al. 2025 (PMID 40493162) found epitalon reduced ROS and restored wound healing in human retinal pigment epithelial cells under high-glucose conditions, an independent Italian study 6.

Antioxidant activity has the most cross-group independent support of the three mechanistic claims.

needs-human-replication — All antioxidant data are in vitro or in non-aging animal/cell models.

3. Melatonin synthesis stimulation (pineal modulation)

Claim: Epitalon acts on pineal gland cells to stimulate melatonin synthesis, partially explaining geroprotective effects via the melatonin axis.

  • Khavinson et al. 2012 (PMID 22816096, Khavinson group) showed that epithalone stimulated AANAT enzyme activity and pCREB synthesis in rat pinealocyte culture, increasing melatonin levels in culture medium 7.

Assessment: This is a Khavinson-group in-vitro result in rat pinealocytes. The mechanistic link from systemic peptide administration → pineal cell melatonin production → geroprotection is multi-step and not established in vivo. Melatonin itself has anti-aging evidence in model organisms but the epitalon-melatonin connection is not independently validated. This mechanism is plausible but speculative.

needs-replication — No independent replication of the melatonin-stimulation claim.

Preclinical evidence

Drosophila melanogaster (synthetic epitalon)

Khavinson et al. 2000 (PMID 11087911, Mechanisms of Ageing and Development) reported that epitalon added only during developmental stages extended lifespan by 11–16% in Canton-S Drosophila at extremely low concentrations (in the picomolar-nanomolar range) 8. The dose-independence of the effect was noted as unusual by the authors. No independent replication has been published.

CBA mice (synthetic epitalon)

Anisimov et al. 2001 (PMID 11227856, Russian-language journal) reported that subcutaneous injection of synthetic epithalon from age 6 months until death in female CBA mice slowed estrus cessation, decelerated free radical processes, and prolonged lifespan while reducing spontaneous tumor incidence 9. needs-replication; Khavinson-group source; Russian-language original.

Rats under aberrant lighting

Vinogradova et al. 2008 (PMID 19110597) and 2007 (PMID 18856211) tested epithalon (0.1 μg/rat, 5×/week) in male and female rats under permanent or natural (non-standard) illumination. Under constant light, epithalon did not extend mean lifespan but normalized population aging rates and significantly inhibited spontaneous tumor development (leukemia, leydigomas in males; tumors in females) 10. These are Khavinson-group-affiliated studies.

HER-2/neu transgenic mice

Semenchenko et al. 2004 (PMID 15501020) applied a semi-parametric frailty model to examine epitalon and melatonin effects on survival in HER-2/neu transgenic mice 11. Frailty-model analysis was used, reflecting interest in heterogeneity of aging response.

Human evidence — CRITICAL DISAMBIGUATION

The widely-cited 266-person mortality cohort used epithalamin (bovine extract), not synthetic epitalon. Claims citing this cohort as evidence for synthetic epitalon are incorrect.

Epithalamin (bovine extract) human cohort data

Khavinson and Morozov 2003 (PMID 14523363) — A prospective study of 266 elderly and older persons conducted at the St. Petersburg Institute of Bioregulation and Gerontology, observing participants for 6–8 years 12. Thymalin (thymic extract) and Epithalamin (pineal extract) were applied for the first 2–3 years of observation. The publication is listed as “randomized controlled trial” in PubMed, but control group composition, allocation method, blinding, and baseline characteristics are not specified in the abstract. Results: Epithalamin-treated group showed a 1.6–1.8-fold reduction in mortality compared to controls over 6 years; Thymalin-treated showed 2.0–2.1-fold reduction; combination treatment 2.5–4.1-fold reduction.

Korkushko et al. 2006 (PMID 17426848, doi:10.1007/s10517-006-0365-z) — A 12-year randomized clinical study of epithalamine (pineal peptide preparation) in elderly patients with coronary disease and accelerated cardiovascular aging 13. Reported 28% lower all-cause mortality in treated vs. control group; cardiovascular mortality 2-fold lower; exercise tolerance improved. Control group received standard therapy only. N per group not specified in abstract.

Methodological concerns for both cohort studies:

  1. Both used epithalamin (extract), not synthetic epitalon.
  2. Control group selection criteria and randomization method not described in accessible abstracts.
  3. Khavinson 2003 was two-site (St. Petersburg + Institute of Gerontology, Kiev); Korkushko 2006 was also Kiev-based. Both involve Khavinson group co-authorship; no external-group independent replication exists.
  4. Cardiovascular-disease patient population — not representative of general healthy aging.
  5. Blinding status unclear.
  6. No biomarker data linking epithalamin administration to mechanism.

needs-replication — No independent research group has replicated the Khavinson mortality-cohort results, either for epithalamin or for synthetic epitalon.

Synthetic epitalon in humans

No published randomized controlled trial of synthetic epitalon in humans has been identified. No ClinicalTrials.gov trials registered as of 2026-05-09.

The compound is sold as a supplement and used in “longevity clinics,” primarily in injectable form, outside any registered trial framework.

Recent independent findings (2022–2025)

Yue et al. 2022 (PMID 35413689) — Mouse oocyte protection at 0.1 mM in vitro; independent Chinese group 5.

Khavinson et al. 2020 (PMID 32019204) — AEDG peptide stimulates neurogenic gene expression (Nestin, GAP43, β-Tubulin III, Doublecortin) by 1.6–1.8× in human gingival mesenchymal stem cells undergoing neuronal differentiation, via proposed epigenetic histone interactions 14.

Al-Dulaimi et al. 2025 (PMID 40908429) — First independent (Brunel University London) cell-line study. Key finding: telomerase activation (hTERT mRNA + enzyme activity) in normal cells; ALT activation (not telomerase) in cancer cells; telomere elongation in all tested cell types 3. Note: an erratum was published (10.1007/s10522-025-10326-8).

Araj et al. 2025 (PMID 40141333) — Independent review from Medical University of Warsaw summarizing 25 years of epitalon research; acknowledges that “it remains uncertain whether [documented effects] are the sole mechanisms of action” 15.

Gatta et al. 2025 (PMID 40493162) — Independent Italian study showing epitalon restores wound healing in diabetic retinopathy cell model via ROS reduction 6.

Safety and regulatory status

  • Not FDA-approved for any indication.
  • Not a licensed pharmaceutical in Western jurisdictions.
  • Sold as a research peptide and supplement; injectable formulations circulate via grey-market supplement channels.
  • No dedicated long-term human safety study identified.
  • Cancer risk: telomerase activation in somatic cells is a theoretical oncogenic concern. Al-Dulaimi 2025 notes ALT activation in cancer cell lines at tested doses — this warrants further safety evaluation before systemic human use.

long-term-unknown — No controlled long-term human safety data.

Aging-relevance framing

Epitalon is positioned in the longevity community primarily as a telomerase activator targeting telomere-attrition, a canonical hallmark of aging. The mechanistic logic is coherent: shortened telomeres drive replicative senescence; telomerase reactivation could extend replicative capacity. However:

  1. The telomere-extension claim in human somatic cells rests on fetal fibroblast studies with a single donor source and no bp-quantification — methodologically weak.
  2. The mortality-reduction claim in humans derives from the bovine extract (not the synthetic peptide) and from a single unreplicated group.
  3. The compound does appear in the DrugAge spirit (lifespan effects in Drosophila and mice from Khavinson group), but no independent animal-lifespan studies exist.

The 2025 independent review (Araj et al.) and the 2025 independent telomere study (Al-Dulaimi et al.) represent a meaningful, if early, shift toward external validation — but the evidentiary base remains thin relative to the compound’s reputation in longevity circles.

R16 intervention matrix

  • Hallmarks linked: telomere-attrition, cellular-senescence
  • Mechanism class check: telomerase-activation — exists in intervention-classes.md (added R28). antioxidant — exists.
  • Note on melatonin-synthesis/pineal-modulation mechanism: The claimed neuroendocrine mechanism (epitalon → pineal AANAT → melatonin upregulation) does not map to any existing class in intervention-classes.md. Documented here as body prose; escalation required — a pineal-neuroendocrine-modulation class may be warranted if more peptides in this cluster share this mechanism. See summary for schema-gap note.
  • Matrix row check: telomere-attrition and cellular-senescence both exist in hallmarks/; Dataview block under telomerase-activation in intervention-classes.md will pick up this page correctly.

Knowledge gaps

GapTagNotes
No human RCT of synthetic epitalonneeds-human-replicationAll human mortality data used epithalamin (bovine extract)
Telomerase-induction mechanism unknownno-mechanismHow AEDG engages TERT promoter in somatic cells not established
Telomere elongation not quantified (bp)needs-replicationKhavinson 2003/2004 report only relative qualitative elongation
No independent animal lifespan replicationneeds-replicationAll Drosophila and mouse data from Khavinson group
Long-term human safety unknownlong-term-unknownInjectable supplement use in humans with no safety study
No ChEMBL or DrugBank entryneeds-canonical-idOnly PubChem CID confirmed
Epithalamin extract composition unstandardizedunsourcedBovine pineal extract is a complex mixture; lot-to-lot variation unknown
Cancer risk of telomerase activation untestedlong-term-unknownTheoretical; ALT activation in cancer lines noted in Al-Dulaimi 2025

Footnotes

Footnotes

  1. doi:10.1023/a:1025493705728 · Khavinson VKh, Bondarev IE, Butyugov AA · Bull Exp Biol Med 2003 Jun;135(6):590–592 · PMID 12937682 · in-vitro · model: telomerase-negative human fetal fibroblast culture (also HeLa cells per Araj 2025 review) · reported: induction of TERT catalytic subunit expression, telomerase enzymatic activity, and telomere elongation; no quantitative bp measurement; single-group study; Khavinson-group source · abstract-verified via PubMed efetch 2026-05-09; full PDF not available (closed-access, not_oa per a local paper archive) no-fulltext-access ↩

  2. doi:10.1023/b:bebm.0000038164.49947.8c · Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD · Bull Exp Biol Med 2004 May;137(5):503–506 · PMID 15455129 · in-vitro · model: primary pulmonary fibroblasts from a single 24-week fetus; cells had lost proliferative potential at passage 34 (mean telomere size “appreciably lower than during early passages, passage 10”) · reported: Epithalon induced telomere elongation to size comparable to early passages; treated cells made 10 extra divisions (reaching passage 44 vs control arrest at passage 34); paper frames this as overcoming the Hayflick limit · no bp-level quantification reported; single donor; Khavinson-group source · abstract-verified via PubMed efetch 2026-05-09; full PDF not available (closed-access, not_oa per a local paper archive) no-fulltext-access ↩

  3. doi:10.1007/s10522-025-10315-x · Al-Dulaimi S, Thomas R, Matta S, Roberts T · Biogerontology 2025;26(5):178 · PMID 40908429 · PMCID PMC12411320 · in-vitro · model: breast cancer lines (21NT, BT474; 0.1–1.0 μg/mL × 4 days) + normal fibroblasts IBR.3 and epithelial cells HMEC (1.0 μg/mL × 3 weeks) · in normal cells: significant hTERT mRNA upregulation and telomerase enzyme activity increase (fourfold IBR.3, 26-fold HMEC); telomere elongation confirmed · in cancer cells: hTERT elevated but telomerase enzyme activity NOT significantly increased; telomere elongation via ALT (~10-fold ALT in 21NT, ~3-fold in BT474 by C-circle assay) · first independent (Brunel University London + Royal Brompton Hospital) replication outside Khavinson group · erratum: doi:10.1007/s10522-025-10326-8 · full-PDF verified 2026-05-09 · archive: locally available ↩ ↩2

  4. PMID 15990728 · Khavinson V, Shataeva L, Chernova A · Neuro Endocrinology Letters 2005;26(6):559–566 · in-silico / biophysical · proposed model for epitalon binding ATTTTC sequence in TERT promoter region; speculative; not biochemically validated · Khavinson-group source ↩

  5. doi:10.18632/aging.204007 · Yue X, Liu SL, Guo JN, Meng TG, Zhang XR, Li HX, Song CY, Wang ZB, Schatten H, Sun QY, Guo XP · Aging (Albany NY) 2022;14(7):3191–3202 · PMID 35413689 · in-vitro · model: post-ovulatory aging mouse oocytes; 0.1 mM epitalon (lower doses 0.05 mM also effective; higher doses 1–2 mM did not reduce ROS — non-monotonic dose response) · primary findings: significantly reduced intracellular ROS (p<0.01 at 24h); spindle defect reduction significant at 24h only (not at 12h); reduced abnormal cortical granule distribution at 12h and 24h; increased mitochondrial membrane potential (p<0.01); increased mtDNA copy number (p<0.001); reduced early apoptosis · independent group: Shanxi Medical University + Chinese Academy of Sciences State Key Lab of Stem Cell and Reproductive Biology · full-PDF verified 2026-05-09 · archive: locally available ↩ ↩2

  6. doi:10.1007/s12015-025-10911-x · Gatta M, Dovizio M, Milillo C et al. · Stem Cell Reviews and Reports 2025 · in-vitro · model: ARPE-19 human retinal pigment epithelial cells under high-glucose conditions · epitalon restored wound healing, reduced ROS, inhibited EMT and fibrosis; independent Italian group · abstract-only verification 2026-05-09 · archive: pending download (hybrid OA) ↩ ↩2

  7. PMID 22816096 · Khavinson VKh, Linkova NS, Kvetnoy IM et al. · Bull Exp Biol Med 2012;153(2):255–259 · in-vitro · model: rat pinealocytes · epithalone stimulated AANAT enzyme and pCREB synthesis, increased melatonin in culture medium; Khavinson-group source; not independently replicated ↩

  8. PMID 11087911 · Khavinson VK, Izmaylov DM, Obukhova LK, Malinin VV · Mech Ageing Dev 2000;120(1-3):141–149 · in-vivo · model: Canton-S Drosophila melanogaster · reported 11–16% lifespan extension at picomolar–nanomolar concentrations; effect dose-independent; Khavinson-group source; no independent replication published ↩

  9. PMID 11227856 · Anisimov VN, Khavinson VKh, Zavarzina NIu et al. · Ross Fiziol Zh Im I M Sechenova 2001;87(2):125–136 · Russian-language journal · in-vivo · model: female CBA mice, SC injection from age 6 months · reported slowed estrus cessation, reduced free radical processes, prolonged lifespan; Khavinson-group source · Russian-language original; abstract-only verification ↩

  10. PMID 19110597 · Vinogradova IA, Bukalev AV, Zabezhinski MA et al. · Bull Exp Biol Med 2008;146(6):627–630 · in-vivo · model: male rats under aberrant lighting regimens · epithalon 0.1 μg/rat 5×/wk; no mean lifespan extension but normalized aging rates and inhibited tumor development; affiliated with Khavinson-group network ↩

  11. PMID 15501020 · Semenchenko GV, Anisimov VN, Yashin AI · Exp Gerontol 2004;39(11-12):1601–1609 · in-vivo · model: female HER-2/neu transgenic mice · frailty-model analysis of epitalon + melatonin vs stressor conditions ↩

  12. PMID 14523363 · Khavinson VKh, Morozov VG · Neuroendocrinology Letters 2003;24(3-4):233–240 · n=266 total across all treatment groups · model: elderly/older humans, 6–8 year follow-up · critical note: intervention was Epithalamin (thymic/pineal peptide bioregulators — specifically Thymalin=thymic, Epithalamin=pineal extract), NOT synthetic epitalon · bioregulators applied for first 2–3 years of observation · mortality reduction: Thymalin 2.0–2.1-fold; Epithalamin 1.6–1.8-fold; Thymalin+Epithalamin 2.5-fold; annual combined (6 yr) 4.1-fold · additional benefits: 2.0–2.4-fold decrease in acute respiratory disease; reduced IHD, hypertension, osteoarthritis, osteoporosis · control group selection, randomization method, and blinding not described in abstract · two-site (St. Petersburg + Kiev); Khavinson-group primary · abstract-verified via PubMed efetch 2026-05-09; full PDF not available (no DOI resolvable; journal not in a local paper archive) no-fulltext-access ↩

  13. doi:10.1007/s10517-006-0365-z · Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA · Bull Exp Biol Med 2006;142(3):356–359 · PMID 17426848 · 12-year randomized clinical study · model: elderly patients with coronary disease and accelerated cardiovascular aging · critical note: intervention was epithalamine (pineal gland peptide preparation = bovine extract), NOT synthetic epitalon · n per group not specified in abstract · findings: 28% lower all-cause mortality in treated vs control (same basic therapy in both arms); cardiovascular mortality 2-fold lower; cardiovascular failure and respiratory disease incidence 2-fold lower; exercise tolerance increased; functional/cardiovascular age decreased · two institutions: Institute of Gerontology, Kiev + Khavinson group · abstract-verified via PubMed efetch 2026-05-09; full PDF not available (closed-access, not_oa per a local paper archive) no-fulltext-access ↩

  14. doi:10.3390/molecules25030609 · Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B · Molecules 2020;25(3):609 · PMCID PMC7037223 · in-vitro · model: human gingival mesenchymal stem cells (gMSCs) under neuronal differentiation · AEDG peptide stimulated mRNA expression of Nestin, GAP43, β-Tubulin III, and Doublecortin by 1.6–1.8× (p<0.01) compared to control; proposed mechanism: epigenetic histone interactions (AEDG binds H1 linker histone) · Khavinson-group with Italian co-authors (Chieti-Pescara) · full-PDF verified 2026-05-09 · archive: locally available ↩

  15. doi:10.3390/ijms26062691 · Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł · Int J Mol Sci 2025 Mar 17;26(6):2691 · review · independent (Medical University of Warsaw, Faculty of Pharmacy; Nicolaus Copernicus University, Bydgoszcz) · 30-page systematic review of 25 years of epitalon research covering in-vitro, in-vivo, in-silico studies, and clinical trials; concludes mechanism of action remains unclear despite statistically significant geroprotective and neuroendocrine effects documented across multiple systems; notes particular lack of physico-chemical characterization; Drosophila lifespan extension confirmed as “up to 16%”; clinical trial data (Retinitis pigmentosa, 162 patients) and human circadian study (75 women) reviewed; confirms epithalamin/epitalon disambiguation throughout · full-PDF verified 2026-05-09 · archive: locally available ↩

Graph View

Backlinks